Targeting Cancer of Unmet Need

Targeting Cancer of Unmet Need

Patients with cancers of unmet need are faced with limited treatment options, and poor 5-year survival rates that have not improved in recent years despite continuing advances in cancer research.

Our mission is to develop novel treatments that can be used in combination with first line therapies to improve survival outcomes and the quality of life of these patients.

New Small Molecule Therapies

Varsity partners with leading oncology academics in Cambridge, and globally, to identify new targets to address drug resistance and develop new small molecule therapies for several resistant cancers.

Varsity works to transform these novel discoveries into new therapies for patients by supporting the clinical development work needed for their eventual regulatory approval and distribution.

About us

Varsity Pharmaceuticals was founded in Cambridge in 2020 as an Oncology focused sister company to the Rare Disease focused Cycle Pharmaceuticals, both part of the Cycle Group. Varsity is ideally placed to use the Cycle Group drug development expertise to support the transformation of world leading oncology research in to life-changing treatments for cancer patients.

Visit to learn more about Cycle.


Varsity Licenses Pol-Theta Inhibitor

Varsity today announced that it has secured exclusive rights from Dana-Farber Cancer Institute to develop and commercialize Novobiocin, a potential first-in-class DNA Pol-theta inhibitor for the treatment of Homologous Recombination (HR) deficient cancers.




VP-006 Pol-Theta Inhibitor - Novobiocin
HR Deficient (HR-) Cancers
Pancreatic Cancer
VP-003 Beta-2 Adrenergic Antagonist
Glioblastoma Multiforme (GBM)
VP-004 PKC Inhibitor
Chronic Lymphocytic Leukemia
VP-005 Gold Complexes
Breast Cancer


VP-006 Pol-Theta Inhibitor - Novobiocin
HR- Cancer Trial Starting 2022
Pancreatic Cancer Trial Starting 2023
VP-003 Beta-2 Adrenergic Antagonist
GBM Trial Starting 2023
VP-004 PKC Inhibitor
CLL Trial Starting 2023
VP-005 Gold Complexes
Breast Cancer Trial 2023

Contact Info

Email Address

Main Office Address

The Broers Building, 21 JJ Thomson Avenue, Cambridge, CB3 0FA, United Kingdom